TEVA PHARMACEUTICAL INDUSTRIES LIMITED

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Previous company name

Name change date

Company Overview
Teva Pharmaceutical Industries Ltd is a global pharmaceutical company specializing in the development, production, and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceutical ingredients. The company was established in 1901, as a small wholesale drug business in Jerusalem that distributed imported medicines loaded onto the backs of camels and donkeys, to customers throughout the land. The company was called Salomon, Levin and Elstein Ltd., after its founders. The company’s headquarters is located in Petach Tikva, Israel.
Teva Pharmaceutical Industries is one of the largest generic pharmaceutical companies in the world. The company offers the widest range of cost-effective pharmaceuticals, both generic and branded, to consumers, customers, and healthcare providers. The company produces generic drugs in all major therapeutics and steriles in a variety of dosage forms, from tablets and capsules to ointments, creams and liquids. The company’s innovative products are developed for specialized markets with the current focus on neurological disorders and auto-immune diseases which maintains the ongoing collaborative efforts with Israel’s major universities, hospitals and research institutes.
Teva Pharmaceutical Industries has novel treatments for MS, Parkinson’s disease (PD), Alzheimer’s disease (AD), epilepsy and other CNS indications as well as Systemic Lupus Erythematosus in clinical research phases. In addition, the company manufactures innovative drugs in niche markets where it has a relative advantage in research and development. The company’s products for the treatment of certain diseases include Copaxone and Azilect. The company also offers fully-integrated pharmaceuticals, human pharmaceuticals, and Active Pharmaceutical Ingredients (API).
Teva Pharmaceutical Industries’ vision is to become one of the world’s leading pharmaceutical companies, by being the undisputed leader in the global Generics industry and by developing a global franchise in selected Innovative products originating from Israeli science.
Teva Pharmaceutical Industries is active in Europe, North America, Latin America, Asia and Africa. The company’s production facilities are located in Israel, Japan, India, the Netherlands, Hungary, the USA, and Mexico. The company has marketing offices and distribution centers in Singapore, Japan, Kenya, the Netherlands, Mexico, Brazil, the USA, Canada, Ireland, Germany, Austria, Scandinavian countries, Poland, Slovakia, Greece, Switzerland, Estonia, Spain, and the United Kingdom.
Business Summary
The Company is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories.
Description and history
The Company is a global pharmaceutical company that develops, produces and markets generic drugs covering all treatment categories.

The Company’s principal products include Copaxone for multiple sclerosis; and Azilect for Parkinson’s disease. The Company also provides specialty pharmaceutical products, which include respiratory products based on its proprietary delivery systems, including Easi-Breathe, an advanced breath-activated inhaler; Spiromax/Airmax, a multidose dry powder inhaler; Steri-Nebs, the blow-fill-seal based nebulizers; and Cyclohaler, a single dose dry powder device. The Company’s branded respiratory products include ProAir, a short-acting beta-agonist for the treatment of bronchial spasms and exercise-induced bronchospasm; and Qvar, an inhaled corticosteroid for long-term control of chronic bronchial asthma. In addition, it offers APIs for respiratory, cardiovascular, anti-cholesterol, central nervous system, dermatological, hormones, anti-inflammatory, oncology, immunosuppressants, and muscle relaxants. Further, the Company provides women s health care products, such as oral contraceptives, intrauterine contraception, and hormone therapy treatments for menopause/perimenopause, as well as therapies for use in infertility and urinary incontinence. It also holds a biotechnology platform focused on the development of peptide and protein-based medicines. The Company has cooperation agreements with Kowa Company, Ltd.; Lonza Group Ltd.; H. Lundbeck A/S; Impax Laboratories, Inc.; Anchen Pharmaceuticals, Inc.; sanofi-aventis; and OncoGenex Pharmaceuticals.

History:

1944 – The Company was incorporated in Israel on February 13, 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901 and is headquartered in Petach Tikva, Israel.

1951 – The Company’s ordinary shares have been listed on the Tel Aviv Stock Exchange.

1982 – The Company’s ADRs have been traded in the United States.

1987 – The Company’s ADRs were admitted to trading on the Nasdaq National Market.

2000 – The Company effected a 2-for-1 stock split. Each holder of an ordinary share, or an ADR, as the case may be, was issued another share. All figures in this annual report have been adjusted to reflect the stock splits.

2002 – The Company effected a 2-for-1 stock split. Each holder of an ordinary share, or an ADR, as the case may be, was issued another share. All figures in this annual report have been adjusted to reflect the stock splits.

2002 – In November 2002, the Company was added to the NASDAQ 100 Index.

2004 – The Company effected a 2-for-1 stock split. Each holder of an ordinary share, or an ADR, as the case may be, was issued another share. All figures in this annual report have been adjusted to reflect the stock splits.

2006 – The Company completed its acquisition of Ivax Corporation, a multinational generic pharmaceutical company with headquarters in Miami, Florida and with operations mainly in the United States, Europe and Latin America, for approximately $3.8 billion in cash and 123 million ADRs. For accounting purposes, the transaction was valued at $7.9 billion, based on the value of the ADRs during the five trading day period commencing two trading days before the date of the merger agreement with Ivax.

Established as a small wholesale drug business in Jerusalem that distributed imported medicines loaded onto the backs of camels and donkeys, to customers throughout the land

Business Line
Development, production, and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceutical ingredients
Subsidiary
2 QUAKER RD INC
Advisor
KESSELMAN & KESSELMAN / ISRAEL
IPO date
1/1/1951
US SIC Code
2834
Company Address
5, Basel Street

City province or state postal code
49131, PETACH TIKVA
Phone: +972 3 9267267
Fax: +972 3 9267472
Country address: ISRAEL
Website url: www.tevapharm.com